A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY)

Keytruda (pembrolizumab) - Merck (MSD)

NG-350A - PsiOxus

https://www.abstractsonline.com/pp8/#!/10517/presentation/20309

Tom Lillie, Mark O'Hara, Christian Ottensmeier, Eileen Parkes, Lee Rosen, David Krige, Marya Chaney, Jo Carter, Vladimir Evilevitch, Matthew Thomas, Aung Naing

Mar 9, 2022